Articles by author - Jan Hrabeta

Impact of histone deacetylase inhibitor valproic acid on the anticancer effect of etoposide on neuroblastoma cells.

Groh T, Hrabeta J, Poljakova J, Eckschlager T, Stiborova M.

Journal Article 2012; 33(Suppl 3): 16-24 PubMed PMID: 23353839  Keywords:  Antineoplastic Agents, Phytogenic:pharmacology, Apoptosis:drug effects, Bone Marrow Neoplasms:drug therapy, Brain Neoplasms:drug therapy, Cell Cycle:drug effects, Cell Line, Tumor, Drug Resistance, Neoplasm:drug effects, Drug Synergism, Etoposide:pharmaco.    Citation

OBJECTIVES: Etoposide (Vepesid, VP-16), an inhibitor of topoisomerase II, is a chemotherapeutic drug commonly used for treatment of differ.....

Read abstract  Full text PDF

Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma.

Poljakova J, Hrebackova J, Dvorakova M, Moserova M, Eckschlager T, Hrabeta J, Göttlicherova M, Kopejtkova B, Frei E, Kizek R, Stiborova M.

Journal Article 2011; 32(Suppl 1): 101-116 PubMed PMID: 22167207  Keywords:  Animals, Antineoplastic Combined Chemotherapy Protocols:pharmacology, Brain Neoplasms:drug therapy, DNA Damage, Dose-Response Relationship, Drug, Drug Evaluation, Preclinical, Ellipticines:administration & dosage, Histone Deacetylase Inhibitors:administra.    Citation

OBJECTIVES: Valproic acid (VPA) and trichostatin A (TSA) exert antitumor activity as histone deacetylase inhibitors, whereas ellipticine a.....

Read abstract  Full text PDF